Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Viesca

Interventional Pain Medicine El Paso, TX Medical Doctor

NPI 1609856194 CMS profile 344823

1000 N Mesa St, El Paso, TX 79902

Open in the dashboard

General payments

$33,921

489 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,780 paid to institutions, not to them · program year 2025

Through program year 2025, Carlos Viesca of El Paso, TX is reported in the CMS Open Payments database as having received $33,921 across 489 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,780 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,755 63
2024 General $6,028 134
2023 General $6,185 79
2022 General $5,043 80
2021 General $5,028 82
2020 General $7,159 36
2019 General $723 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Viesca
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Carlos Viesca were reported at $3,755. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Carlos Viesca Interventional Pain Medicine median Middle half National median
2019 $723 $684 $216–$2,079 $163
2020 $7,159 $382 $122–$1,109 $114
2021 $5,028 $552 $167–$1,554 $132
2022 $5,043 $605 $187–$1,924 $149
2023 $6,185 $671 $195–$1,915 $160
2024 $6,028 $684 $206–$1,837 $164
2025 $3,755 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $11,598 192 payments
  2. Medtronic USA, Inc. $5,539 25 payments
  3. Boston Scientific Corporation $2,679 35 payments
  4. Abbott Laboratories $2,391 51 payments
  5. Nalu Medical, Inc. $2,016 60 payments
  6. Vertos Medical, Inc. $1,909 10 payments
  7. Relievant Medsystems, Inc. $1,815 14 payments
  8. Spinefrontier, Inc. $1,035 3 payments
  9. BIOTRONIK NRO, Inc. $996 14 payments
  10. Orthofix Medical, Inc. $695 6 payments
  11. Other $3,248 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,010 450 payments
  2. Travel and Lodging $7,254 34 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,410 2 payments
  4. Education $1,211 2 payments
  5. Entertainment $36 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS Spinal Cord Neurostimulation $4,868 13 payments
  2. INTELLIS ADAPTIVESTIM $4,664 69 payments
  3. Nalu Neurostimulation System $2,016 60 payments
  4. Intracept Pain $1,954 15 payments
  5. mild Device Kit $1,909 10 payments
  6. Intracept Pain $1,815 14 payments
  7. Intracept Pain $1,815 14 payments
  8. Intracept Pain $1,815 14 payments
  9. INTELLIS Spinal Cord Neurostimulation $1,655 28 payments
  10. General - Therapies $1,420 6 payments
  11. Other $17,243 296 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

9,597

Median for Pain Management: 951

Drug cost

$393,400

Median for Pain Management: $26,034

Branded share of claims

37.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,542 $80,632
Xtampza Er Oxycodone Myristate Brand 135 $77,640
Belbuca Buprenorphine Hcl Brand 26 $20,437
Fentanyl Generic 165 $18,631
Nucynta Er Tapentadol Hcl Brand 13 $18,341
Buprenorphine Generic 71 $17,674
Oxycontin Oxycodone Hcl Brand 23 $13,911
Diclofenac Sodium Generic 210 $12,327
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 353 $12,143
Pregabalin Generic 633 $11,067

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$268,274

Of which drugs: $585

Medicare patients

265

Average age 74

Services billed

5,015

165 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 45%
Chronic kidney disease 33%
Depression 31%
Ischemic heart disease 29%
Osteoporosis 26%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 86 614 $342
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 61 1,836 $162
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 30 256 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

489 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record